


1502
Kishore

1502

MCGREGOR & ADLER
A PROFESSIONAL CORPORATION



P.O. BOX 710509
HOUSTON, TEXAS 77271-0509

WRITER'S DIRECT DIAL
(713)-777-2321
WRITER'S DIRECT FACS.
(713)-777-6908
E. MAIL: BAADLER@i-link.net

INTELLECTUAL PROPERTY LAW
(PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW)

January 14, 1998

FACSIMILE COVER SHEET

PLEASE DELIVER TO: Examiner G.S. Kishore, Ph.D.

COMPANY: USPTO-Group 1502

FACSIMILE NUMBER: (703) 305-5408

NUMBER OF PAGES (COUNTING COVER SHEET): 7

FROM: Dr. Benjamin Adler

MESSAGE: Please deliver to Examiner Kishore. Thanks, Dr. Adler

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of this transmittal, the information contained in this facsimile is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader is not the intended recipient or an employee or agent responsible for delivery, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please immediately notify Dr. Benjamin Adler at (713) 777-2321 and promptly return the facsimile. Thank you.

*8/ Reg for
Recons*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:
T. STEINEMANN ET AL.

§ ART UNIT: 1502

FILED: May 4, 1994

§
§
§ EXAMINER:
§ KISHORE, G.

SERIAL NO.: 08/580,384

FOR: NOVEL OPHTHALMOLOGIC
USES OF PROTEIN C

§ DOCKET: D5715D

Ref
-21-98
RECEIVED
*1-14-98*Assistant Commissioner of Patents
BOX NON-FEE
Washington, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this Response is being transmitted via facsimile to
the Patent Office on January 14, 1998.*Benjamin Aaron Adler*
Benjamin Aaron Adler, Ph.D., J.D.

RESPONSE

Dear Sir:

Responsive to the Final Office Action mailed October 14, 1997,
please enter the following amendments.REMARKSApplicant submits the following remarks. Reconsideration of
this application in view of the remarks is respectfully requested.The 35 USC §103 RejectionsClaims 22-27 stand rejected under 35 USC §103(a) as being
unpatentable over **Galin** et al. or **Iverson** et al. in combination with **Bang**
et al. and **Esmon** et al. Claims 28-29 stand rejected under 35 USC §103(a)
as being unpatentable over **Galin** et al. or **Iverson** et al. in combination